{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "SEER", "name": "Seer, Inc.", "url": "https://frontierpicks.com/dossiers/SEER/", "json_url": "https://frontierpicks.com/dossiers/SEER.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the 2026-08-21 close of $2.03. Q2 missed both lines and cash fell to $209.5M. No company-dated catalyst inside 30 days.", "invalidation_trigger": "A daily close below $1.95 gives back the 2026-07-06 gap shelf; compounded if a further 30 days pass from the 2026-08-13 demand letter with no 8-K or press release disclosing an evaluation timeline, a Special Committee counter, or a definitive agreement.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "m-and-a-special-situations", "medtech-diagnostics", "small-cap-value-rotation" ], "tags": [], "sources": [], "notes": [ "Dual-class structure: Class B carries ten votes per share and converts 1:1 into Class A; both live proposals are for Class A shares only.", "Both acquisition proposals remain non-binding. No definitive merger agreement has been announced by either bidder as of 2026-08-21.", "Neither CVR structure has a disclosed floor: the $0.33, $4.91 and 85%-of-net-proceeds figures are caps or formulas, not minimum payments.", "Micro-cap with ~54.98M shares outstanding as of 2026-07-25; headline-driven single-session moves above 30% have already occurred in this cycle.", "The Special Committee is two directors, Meeta Gulyani and Nicolas Roelofs; Perella Weinberg Partners is financial advisor and Wilson Sonsini is legal counsel.", "One bidder is the sitting Chair and CEO, so proposal-related disclosure carries an inherent conflict that the Special Committee structure exists to manage." ], "body_markdown": "## Current Thesis\nThe leg on offer is an M&A endgame: four non-binding take-private proposals between 2026-07-01 and 2026-07-30 from two bidders — the company's own Chair/CEO and a ~7.7% activist group — priced against a reported balance sheet larger than the equity being bid for. Since the last update that ladder has not moved forward, it has moved sideways into a stand-off. The Radoff-JEC proposal of $2.55 per Class A share in cash plus a CVR for 85% of net proceeds from any license, sale or disposition of Seer's assets including PrognomiQ carried a stated expiry of 2026-08-10; on 2026-08-13 the group issued a release stating the proposal \"expired on August 10th\" with \"no answer from the Special Committee,\" and demanded the board publicly acknowledge that Seer needs to be taken private and disclose a timeline for evaluating the offers. Through the 2026-08-21 reference close of $2.03 no company press release or 8-K has answered it.\n\nUnderneath the process, the operating numbers moved the wrong way. Q2 printed 2026-08-11 at $3.1M revenue, down 23% from $4.1M a year earlier and short of the $3.55M consensus, with EPS of -$0.31 against -$0.27. Cash, equivalents and investments were $209.5M at 2026-06-30 ($26.1M cash and equivalents, $183.4M investments) versus approximately $220M at 2026-03-31. FY2026 guidance was reaffirmed at $16–18M against a $16.25M consensus.\n\n**The narrative is saturated.** Every escalation channel has already been used and dated. Bidding stopped on 2026-07-30. The proxy route closed on 2026-07-28 when all seven company nominees were re-elected and the WHITE-card slate was not seated. The highest bid's own deadline lapsed unanswered on 2026-08-10. The only new headline in the eleven sessions to 2026-08-21 is the bidder restating his case on 2026-08-13 — an advocacy release, not a corporate event. The special-situations audience knows the setup in full; what is absent is a new marginal buyer, and the price action says so: RSI(14) at 13.8 on the 2026-08-21 close, a 14.3% distance below the $2.37 52-week high, against a three-month price change of +13.4% that is entirely July's gap. A definitive agreement or a fifth raised bid would reset this toward accelerating; a disclosed process termination would take it to dead.\n\n## Bull Case\n- **Reported liquid assets exceed the cash being offered for the whole equity.** $209.7M-equivalent line item — precisely, $209.5M of cash, equivalents and investments at 2026-06-30 — against roughly 54.98M shares outstanding as of 2026-07-25. Management stated on the 2026-08-11 release that the position funds operations for at least twelve months.\n- **The activist has not withdrawn after his own deadline.** The 2026-08-13 release reiterated the $2.55 cash-plus-CVR terms and the ~7.7% stake rather than announcing an exit, and demanded a disclosed evaluation timeline. A holder that has bid four times and then published a demand letter is still engaged.\n- **The competing structure is still on the table and richer on the headline.** Farokhzad's revised proposal, confirmed received 2026-07-29/30, pairs $2.45 cash with a tiered Revenue-Linked CVR of up to $0.33 per share and a tiered Sale-Linked CVR of up to $4.91 per share — a headline aggregate of up to $7.69 versus $5.61 in the prior version.\n- **Loss narrowed and the Committee's mandate is broad.** Q2 net loss $16.9M versus $19.4M a year earlier, gross margin 49%. On 2026-07-30 the company said the Special Committee would review \"both acquisition proposals and other alternatives,\" with Perella Weinberg Partners as financial advisor and Wilson Sonsini as legal counsel — wider language than the flat rejection issued 2026-07-20.\n- **The $2.55 headline cash number sits above the 2026-08-21 close of $2.03.** INFERRED, not measured: the market is discounting the probability that any of it gets paid, and that discount widened rather than narrowed after the expiry.\n\n## Bear Case\n- **The deadline came and went with silence.** No 8-K, press release or company statement disclosing an extension, a counter, a timeline or a definitive agreement has followed the 2026-08-10 expiry as of 2026-08-21. A binary whose date passes without resolution decays.\n- **The bidder's own read of the process is adversarial.** In the 2026-08-13 release the Radoff-JEC Group described meeting the two-member Special Committee — Meeta Gulyani and Nicolas Roelofs — after the fourth proposal and coming away believing the Committee \"was simply formed to reject bids.\" That is the bidder's characterisation, not a company statement, and it describes a counterparty relationship that has not produced a transaction.\n- **The proxy channel is closed until the next annual meeting.** All seven company nominees were re-elected 2026-07-28. There is no dated governance lever left in 2026.\n- **Two consecutive revenue misses against a reaffirmed range.** $2.8M and $3.1M in the two reported quarters against a full-year $16–18M reaffirmation; the second half carries the entire burden of that range.\n- **Burn is eating the anchor.** Cash, equivalents and investments fell from approximately $220M at 2026-03-31 to $209.5M at 2026-06-30, with first-half free cash flow of approximately -$25.3M. The quantity both proposals are priced against shrinks each quarter the process does not close.\n- **CVRs have no disclosed floor.** The $0.33, $4.91 and 85%-of-net-proceeds figures are caps and formulas. Nothing filed establishes a minimum payment on either structure.\n\n## Setup & Price Structure\nThe 2026-07-06 session is the structural reference: Benzinga recorded shares up 32.1% to $2.14 in that pre-market on the Radoff-JEC \"should not be a public company\" release, and the shelf built off that gap has been the floor for the frame ever since. The 52-week high of $2.37 was set into the late-July bidding, and the reference close of $2.03 on 2026-08-21 sits 14.3% below it.\n\nWhat the tape shows now is one-way drift, not a base. RSI(14) at 13.8 is the observable: persistent selling with no reflexive dip bid appearing across the post-print sessions. Deep oversold readings in a $2 micro-cap are a description of pressure, not a signal of exhaustion — a base would require a series of higher lows and a reclaim of the low-$2.20s where the July bid-ladder highs sit. $1.95 is the level that matters on the downside; a close through it gives back the 2026-07-06 gap and removes the only piece of structure the July campaign built.\n\nCrowding and positioning observables, stated as observables: the activist group holds approximately 7.7%; a GuruFocus screen dated 2026-08-17 reports no insider purchases and 17,963 shares of insider selling across the prior three months, with a price-to-sales ratio of 8.49 against a historical median of 9.56; the Radoff-JEC 2026-08-13 release asserts the CEO has sold \"over $103 million\" of stock since the IPO, which is an advocacy claim by a bidding party rather than a filing summary. There is no company-scheduled event inside the next 30 days to concentrate flow into. Dual-class mechanics remain: Class B carries ten votes per share and converts 1:1 into Class A, and both proposals are for Class A only.\n\n## Catalyst Calendar (next 30 days)\n\n- **No company-confirmed dated event between 2026-08-23 and 2026-09-22.** This is the material fact about the window, not an omission. The 10-Q accompanied the 2026-08-11 print, the annual meeting is done, and no September conference participation for 2026 has been confirmed in a release datable to this year.\n- **Undated but live:** a further Radoff-JEC filing (DFAN14A or a 13D amendment) reflecting a stake change, a fifth proposal, or a withdrawal.\n- **~2026-11-10 (est.):** Q3 2026 results — outside the window, and currently the next hard-dated disclosure of the cash line and the $16–18M range.\n\n## Elapsed catalysts\n\n- **Undated but live:** an 8-K or press release from Seer responding to the 2026-08-13 demand for a disclosed evaluation timeline. Any such filing arrives without warning and is the single highest-information event available. *(passed 13d ago)*\n\n## What Would Change Our Mind\nThe structure that would break first is the 2026-07-06 gap shelf: a daily close below $1.95 gives it back and says the market has repriced the take-private path as a non-event, which is the specific outcome this frame is exposed to. Compounding that would be a further 30 days elapsing past 2026-08-13 with no company 8-K or press release disclosing a timeline, a counter, or a definitive agreement — the demand letter would then have produced the same silence the 2026-08-10 expiry did.\n\nOn the other side, the frame re-rates on a filing, not a chart. A definitive merger agreement, a disclosed extension of the $2.55 proposal, or a Special Committee announcement of a formal sale process with a stated timeline would each restore the escalation leg that stopped on 2026-07-30. A fifth proposal at a higher cash number, or a third-party bidder surfacing through the Perella Weinberg process, would do the same.\n\nThe fundamental datapoint that would flip the standalone half of the argument is the cash line. Q3 cash, equivalents and investments printing materially below $209.5M, or any cut to the $16–18M FY2026 range, removes the balance-sheet anchor that makes a sub-cash bid look like a floor rather than a ceiling.\n\n## Correlation Notes\nSince 2026-07-02 the daily prints have tracked proposal headlines rather than the proteomics and life-science tools tape — the 32.1% pre-market move on 2026-07-06 came off an activist release, not sector news. INFERRED, not measured: correlation to the tools group is suppressed while the bid ladder is formally open and would re-couple sharply if both proposals were confirmed lapsed, at which point the comparison set becomes cash-heavy, revenue-light tools micro-caps rather than merger-arb situations.\n\nTwo other linkages are worth watching. The $183.4M investments portfolio makes a meaningful share of the interest-income line rate-sensitive, so the standalone runway math moves with short rates independently of anything the company does. And the name currently sits in the small-cap special-situations cohort, where flow is driven by process news across unrelated tickers; the eleven Benzinga items in the thirty days to 2026-07-30 followed by near-silence through 2026-08-21 illustrates how quickly that attention pool reallocates when a deadline passes without an announcement.", "first_seen": "2026-08-03", "last_analyzed": "2026-08-23T11:52:10+00:00", "last_synthesized": "2026-08-23", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }